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Background: In 2010 a Cochrane review confirmed that folic acid (FA) supplementation prevents the first- and
second-time occurrence of neural tube defects (NTDs). At present some evidence from observational studies
supports the hypothesis that FA supplementation can reduce the risk of all congenital malformations (CMs) or
the risk of a specific and selected group of them, namely cardiac defects and oral clefts. Furthermore, the effects
on the prevention of prematurity, foetal growth retardation and pre-eclampsia are unclear.
Although the most common recommendation is to take 0.4 mg/day, the problem of the most appropriate dose
of FA is still open.
The aim of this project is to assess the effect a higher dose of peri-conceptional FA supplementation on reducing
the occurrence of all CMs. Other aims include the promotion of pre-conceptional counselling, comparing rates of
selected CMs, miscarriage, pre-eclampsia, preterm birth, small for gestational age, abruptio placentae.
Methods/Design: This project is a joint effort by research groups in Italy and the Netherlands. Women of
childbearing age, who intend to become pregnant within 12 months are eligible for the studies. Women are
randomly assigned to receive 4 mg of FA (treatment in study) or 0.4 mg of FA (referent treatment) daily.
Information on pregnancy outcomes are derived from women-and-physician information.
We foresee to analyze the data considering all the adverse outcomes of pregnancy taken together in a global
end point (e.g.: CMs, miscarriage, pre-eclampsia, preterm birth, small for gestational age). A total of about 1,000
pregnancies need to be evaluated to detect an absolute reduction of the frequency of 8%. Since the sample
size needed for studying outcomes separately is large, this project also promotes an international prospective
meta-analysis.
Discussion: The rationale of these randomized clinical trials (RCTs) is the hypothesis that a higher intake of FA is
related to a higher risk reduction of NTDs, other CMs and other adverse pregnancy outcomes. Our hope is that
these trials will act as catalysers, and lead to other large RCTs studying the effects of this supplementation on CMs
and other infant and maternal outcomes.
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Congenital malformations and other adverse outcomes
Congenital malformations (CMs) are an important pub-
lic health issue in terms of impact on the quality of life
of affected children, adults and their families, and are a
major cause of early spontaneous abortions, termination
of pregnancy, infant morbidity, mortality and disability
in all industrialized countries. Even in the less developed
countries, CMs are recognized as one of the major prob-
lems in the maternal-child health field.
The European Surveillance of Congenital Anomalies
(EUROCAT), a network of population-based congenital
anomaly registries in Europe, currently surveys more
than 1.7 million births per year, including 31% of births
in the European Union. EUROCAT member registries
collect data, ascertained from multiple sources, on all
major structural congenital and chromosomal anomalies:
the prevalence rate of all anomalies, excluding chromo-
somal anomalies, is 219.70 per 10000 births, and the rate
of neural tube defects (NTDs: anencephalus and simi-
lar, spina bifida, encephalocele) is 9.32 per 10000 births
(2007–2011). Across Europe, an estimated 4500 pregnan-
cies are affected by NTDs each year [1].
The economic cost of CMs is very high, including
long-term psychological and socio-economic effects. In
particular, the lifetime direct medical cost for patients
with NTDs is significant, with the majority of cost being
for inpatient care, for treatment at initial diagnosis in
childhood, and for comorbidities in adult life. Caregiver
time costs are also significant [2]. The lifetime indirect
cost for patients with spina bifida is even greater due to
increased morbidity and premature mortality [3].
Considering other adverse pregnancy outcomes, pre-
term birth is the second largest direct cause of child
deaths in children younger than 5 years and preterm
birth complications are estimated to be responsible for
35% of the world’s 3.1 million annual neonatal deaths.
Available evidence suggests that the rate of preterm
birth in high-income countries is rising [4]. The majority
of this increase is due to a rise in the rate of late preterm
births (between 34 and 36 weeks gestation). Preterm
birth, defined as delivery prior to 37 completed weeks, is
a major challenge for maternal and perinatal care world-
wide and a leading cause of neonatal morbidity and
mortality [4-6]. In 2010, an estimated 14.9 million ba-
bies (range 12.3-18.1 million) were born preterm; thisis 11.1% of all live births worldwide, ranging from about
5% in several European countries to 18% in some African
countries. Children born prematurely have higher rates of
learning disabilities, cerebral palsy, sensory deficits and
respiratory illnesses compared to children born at term.
These negative health and developmental effects often
extend to later life, resulting in enormous medical, educa-
tional, psychological and social costs [6-8].
Birth weight is the endpoint of different foetal growth
patterns and adverse exposures that may influence foetal
growth as early as the first trimester. Human growth
and development rates are highest during the first tri-
mester of pregnancy, when essential foetal organ devel-
opment is completed. Foetal developmental adaptations
due to adverse conditions may affect the structure,
physiology and function of various organ systems, leading
to foetal growth restriction and increased risks of
metabolic and cardiovascular disease in adulthood. Foetal
growth restriction is widely recognized as a risk factor for
neonatal mortality and morbidity [9], as well as reduced
cognitive function and the development of chronic dis-
eases in later life [6,10,11].
Regarding maternal adverse outcomes, pre-eclampsia
is a major cause of maternal mortality (15-20% in devel-
oped countries) and morbidities (acute and long-term),
perinatal deaths, preterm birth and intrauterine growth
restriction [12,13]. Despite advances in perinatal care,
frequency of pre-eclampsia has not changed. Several stud-
ies have also suggested that women who develop pre-
eclampsia are at increased risk of cardiovascular compli-
cations later in life [14-16], in particular hypertension,
ischaemic heart disease, stroke, venous thromboembolism,
and death [17].
Primary prevention of these adverse pregnancy out-
comes in the population is a crucial policy priority,
including pre-conceptional care and whole population
approaches [1,7]. Furthermore, finding simple and in-
expensive ways to prevent these infant and maternal
adverse outcomes is salient in any setting [2,18,19].
Folic acid supplementation
Folic acid (FA) (vitamin B9 or pteroyl-L-glutamic acid)
is a water-soluble vitamin of the B group. It is a syn-
thetic product not available in nature, and represents the
main compound in multivitamin products and in cereals
and wheat fortification. The 5-metyl-tetrahydrofolate
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and the FA must be transformed into this molecule in
order to exert its biological function. Folates act as cofac-
tors of enzymes involved in the aminoacid metabolism, in
the DNA and RNA synthesis (purine and pyrimidine syn-
thesis) [20] and, together with vitamin B12, in the methy-
lation of nucleic acids, proteins and lipids [21-23]. A
central feature of foetal development is widespread and
sustained cell division. As a result of its role in nucleic
acid synthesis, the need for folate increases during times
of rapid tissue growth [24]. From the point of view of
preventive medicine and clinical pathology, the study of
the interaction of folate metabolism and that of homocyst-
eine/methionine is particularly promising [25,26].
Folate insufficiency can be due to inadequate dietary
intake, utilization defect, typically in alcohol abuse and
hepatic diseases, malabsorption, increased needs like in
pregnancy and during lactation, interference by drugs
(anti-convulsants, chloramphenicol, methotrexate, oral
contraceptives, pyrimethamine, sulfasalazine and other
sulphamidics, trimethoprim), smoking, deficiency of en-
zymes and cofactors necessary to the generation of active
forms of FA.
Moreover, the folate functional insufficiency is emer-
ging as one of the most common nutritional deficiencies.
The first consequence of even light folate insufficiency is
an increase of plasmatic homocysteine. Such a condition
is clinically silent, but is now recognized as a metabolic
risk factor for many multifactorial diseases [27,28].
The association between folate insufficiency and con-
genital defects has been intensely studied in the past
twenty years. In the context of foetus development
disorders, the NTDs represent the paradigm of the CMs
avoidable by means of FA intake.
In 1991, in a randomized clinical trial (RCT) per-
formed in the 1983–1991 years, the Medical Research
Council Vitamin Study Group [29] showed that 4.0 mg
of peri-conceptional FA supplementation reduced the
risk of recurrence of NTDs by 72% (RR = 0.28, 95% CI
0.12-0.71); in 1992 the Hungarian RCT [30], performed
in the period 1984–1991, showed that supplementation
with multivitamins including 0.8 mg of FA reduced the
risk of the occurrence of the same condition (OR = 0.07,
95% CI 0.04-0.13). These two RCTs have shown conclu-
sively that the risk of NTDs can be reduced substantially
by taking FA during the peri-conceptional period (at least
1 month before the last menstrual period up to the end of
the first trimester of pregnancy). Previous and subsequent
investigations confirm these results [31,32].
In 2010 a Cochrane review [33] confirmed that FA
supplementation prevents the first- and second-time
occurrence of NTDs. Five trials involving 6105 women
(1949 with a history of a pregnancy affected by an NTD
and 4156 with no history of NTDs) were included.Overall, the results were consistent in showing a protect-
ive effect of daily FA supplementation (alone or in com-
bination with other vitamins and minerals) in preventing
NTDs compared with no interventions/placebo or vita-
mins and minerals without FA (RR = 0.28, 95% CI 0.15-
0.52). FA had a significant protective effect for recurrence
(RR = 0.32, 95% CI 0.17-0.60). There were insufficient data
to evaluate the effects on other outcomes such as cleft lip
and palate, congenital cardiovascular defects, or any other
birth defects.
However, the Hungarian RCT [30] and some observa-
tional studies [34-37] suggest that FA may reduce the
risk of CMs overall, or the risk of a specific and selected
group of them [38], namely oral clefts [39-42], cardiac
defects [43-46], urinary tract anomalies except hypospa-
dias [47], limb reduction defects [48], omphalocele [49],
anal atresia [50].
Because more than 10,000 children are estimated to be
born daily with CMs worldwide, even a 15-20% decrease
in the overall risk for birth defects would be important.
The preventive effect of the FA might therefore affect
several CMs, as suggested by the Hungarian cohort-
controlled trial [35], and a case–control study conducted
in Atlanta, United States [36]. These studies observed a
reduction of 47% and 16% respectively in all CMs,
except NTDs. We underline that the Hungarian study
was conducted with 0.8 mg/day and the American one
with an average dose of 0.4 mg/day. It is reasonable to
hypothesize that the percentage of CMs preventable with
a dose of 0.4 mg/day is 20%, and with 4 mg this is at
least 20% greater.
The Hungarian study conducted also shows a 60% risk
reduction of the Down syndrome (OR = 0.4, 95% CI 0.2-
0.7) in women who had taken 6–9 mg/day of FA before
pregnancy [51]. This association was not confirmed in
other conditions [52,53].
Unfortunately, from the observational studies it is
impossible to gain a precise estimate of the reduction
associated with the FA supplementation. A robust study
design as is obtained in an RCT is needed to confirm
these results and obtain a more precise size effect.
Furthermore, the effects of FA supplementation for
the prevention of other infant and maternal outcomes
are unclear.
In 2005 a large RCT of FA supplementation found no
evidence of an effect of supplements on mean birth
weight, placental weight or gestational age at delivery.
There was a possible reduction in risk of low birth weight
or antepartum haemorrhage with high-dose FA supple-
ments, and a possible reduction in risk of pre-eclampsia
with low and high dose [54].
In the recent Cochrane meta-analysis of randomized
and quasi-randomized trials, there were no significant
differences between experimental and control groups on
Bortolus et al. BMC Pregnancy and Childbirth 2014, 14:166 Page 4 of 15
http://www.biomedcentral.com/1471-2393/14/166other pregnancy outcomes [33]. Considering the supple-
mentation with FA versus any other interventions/pla-
cebo, all five trials examined the rate of miscarriage in
women with confirmed pregnancy. While the number of
miscarriages increased in the group receiving supple-
ments containing FA, the difference between groups did
not reach statistical significance (RR = 1.10, 95% CI 0.97-
1.26). The number of babies with low birth weight (less
than 2500 g) was examined in one trial (186 babies).
There was no significant evidence of a difference be-
tween treatment groups. Stillbirths were reported in four
trials. There was no significant evidence of any differ-
ence between treatment groups in the pooled analysis
(RR = 0.96, 95% CI 0.51-1.83). The number of women
affected by multiple pregnancy (2 or more foetuses at
birth) was examined in three trials. Overall there was no
evidence of any significant difference between women re-
ceiving supplements with FA and those in the controls
(RR = 1.32, 95% CI 0.88-1.98). No trials reported results
for preterm birth (less than 37 weeks’ gestation) and pre-
eclampsia, defined as gestational hypertension (blood
pressure higher than 140/90 mmHg) and proteinuria
(more than 300 mg of protein in a 24-hour urine sample).
All of the studies included were published before 2001.
Observational studies have suggested that a higher level
of folate in pregnancy is associated with higher birth
weight, increased placental weight and fewer preterm
births [28,55-57], although these results have not been
confirmed in other populations recently [58]. At present
the association between folate insufficiency and the onset
of placenta-mediated diseases, such as spontaneous abor-
tion [58-65], preterm birth [66-75], foetal growth retard-
ation [76-80], pre-eclampsia [81-88], abruptio placentae
[89] and stillbirth [90] is still not entirely clear.
Moreover, prenatal multivitamins containing FA appear
to be associated with a significant protective effect on
three paediatric cancers: leukaemia (OR = 0.61, 95% CI
0.50-0.74), paediatric brain tumours (OR = 0.73, 95% CI
0.60-0.88) and neuroblastoma (OR = 0.53, 95% CI 0.42-
0.68) [91,92]. Recently, ecological studies provided
support for a decrease in Wilms tumour, neuroblastoma,
primitive neuroectodermal tumours and ependymomas
after Canadian and United States FA fortification [93-95].
It is also of interest to investigate whether maternal
FA supplementation during pregnancy may be associ-
ated with a reduced risk of other neurodevelopmental
disorders in children [96,97]. A recent study of 38,954
children in the Norwegian Mother and Child Cohort
Study found that peri-conceptional maternal intake of
FA supplements was associated with a lower risk of
severe language delay at age 3 years [98]. In the same
cohort, the use of FA supplements around the time
of conception was associated with a lower risk of aut-
istic disorder [99].Peri-conceptional FA supplementation
Supplementation with FA before the time of conception
reduces the risk of NTDs. This protective effect has led
to mandatory flour fortification with FA in several coun-
tries [100], and it is generally recommended that women
planning to become pregnant take a daily supplement
of FA.
These findings led the Public Health Authorities in
some countries (e.g.: United States [101], Canada [102],
Chile [103], Costa Rica [104], South Africa [105], Australia
[106]) to fortify staple food [107-109] and the Depart-
ments of Health of many other countries (mainly in
Europe [110,111]) to recommend that women of child-
bearing age consume an extra 0.4 mg of FA per day to
prevent NTDs.
Supplementation with FA is internationally recom-
mended to women from the moment they try to conceive
until 8–12 weeks of pregnancy. At present the most
common public health recommendation to prevent the
occurrence of NTDs and possibly other CMs is to take an
FA supplement containing 0.4 mg/day [111]. However, the
debates about the most appropriate dose and increasing
FA supplementation in childbearing age are still unre-
solved. With respect to FA dosage, a review of efficacious
doses conducted by Wald et al. [112] suggested a dose-
dependent effect.
It must be realized that the two RCTs clearly showing a
reduced risk of NTDs were performed with 4.0 mg/day
[29] and 0.8 mg/day [30] of FA. Furthermore, a non-
randomized study on the recurrence risk of oral clefts
observed a risk reduction of 66% using a FA peri-
conceptional supplementation of 10 mg/day [113]. A
Hungarian study showed that only a high dose (6 mg/day)
of FA reduced the risk of oral clefts by 25% (OR = 0.75,
95% CI 0.58-0.96) but not a lower dose (<1 mg/day) [114],
and a Hungarian case–control study on Down syndrome
observed a decreased risk of 60% (OR = 0.4, 95% CI 0.2-
0.7) after the pre-conceptional use of a high dose of FA
(6–9 mg/day) [51].
In 1995 Daly et al. showed that NTDs risk was associ-
ated with red blood cell (RBC) folate levels in a continu-
ous dose–response relationship [115]. In this case–control
study, the group of women with the lowest NTDs risk
equal to 0.8 per 1,000 births was the group with RBC
folate levels equal to or higher than 906 nmol/L, with a
group mean of 1,292 nmol/L. According to other experts
[116,117], the concentration of RBC folate of 906 nmol/L
can be considered the most desirable level in early preg-
nancy to reduce the NTDs risk.
However, studies conducted in Europe failed to find
an optimal level of serum folate in these populations
[112,118] and recent data suggest that pregnant women
use high doses of FA supplementation in early- to mid-
pregnancy in several European countries [75,79,119].
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prevention of NTDs and to prevent their occurrence in
epileptic and diabetic mothers is to take a higher dose of
FA, 4–5 mg/day [111]. Furthermore, in 2007 the Canadian
Recommendations also included obesity (BMI >35) as a
health risk and recommended “the higher dose FA strat-
egy (5 mg)” in patients with a history of poor compliance
with medications and additional lifestyle issues of variable
diet, no consistent birth control, and alcohol, tobacco,
and recreational non-prescription drugs use [120,121].
In particular, the use of FA supplements might (partially)
neutralize the adverse effects of smoking on DNA methy-
lation, since folate provides methyl groups for the synthe-
sis of methionine and plays a critical role in homocysteine
metabolism [122-124].
Moreover, women planning to become pregnant might
be exposed to medications with known antifolate activities
affecting different parts of the FA metabolic cascade. Epi-
demiological studies have shown an increased risk of birth
defects or placenta-mediated adverse pregnancy outcomes
among women exposed in early gestation to antiepileptic
drugs (carbamazepine, valproate, barbiturates), sulpho-
namides or methotrexate [125,126]. Hence, whenever
women use these medications, or have used them in the
period prior to conception, they should take 5 mg/day of
FA until the end of the first trimester of pregnancy [121].
Wald et al. [112] addressed the issue of the efficacy of
high FA dosage more comprehensively, assessing the
effect of increasing FA intake on serum folate levels and
on the relation between these levels and the risk of
having NTDs during pregnancy. They found that from a
typical western background serum folate level of 5 ng/mL,
an increase of 0.4 mg/day would reduce the risk of NTDs
by about 36%, while taking 5 mg/day would reduce the
risk by about 85%. A working group convened by the
WHO Regional Office in Europe and Istituto Superiore di
Sanità on 11–12 November 2002 endorsed these estima-
tions [127].
Actually there is no good evidence to advise a different
dose to women without an increased risk, women with a
foetal NTD during a previous pregnancy or women with
another well-known risk factor. If a dose of 4–5 mg/day
can prevent recurrence or occurrence in women with
well-known risk factors, it should be the same for
the occurrence and in women with no known risk
factors.
The question remains concerning the best dose of FA
supplementation, as the prevalence of CMs worldwide is
still high.
Overall, from all these studies it can be speculated that
an increased peri-conceptional intake of FA can cause a
greater reduction in the risk of NTDs as well as a greater
and measurable reduction in the risk of other CMs,
including trisomy 21 syndrome.The hypothesis that a higher intake of FA is related to
a higher risk reduction of NTDs and of other CMs is the
main rationale for the Italian and Dutch RCTs.
FA supplementation in second and third trimester of
pregnancy
During pregnancy, increased folate intake is required for
rapid cell proliferation and tissue growth of the uterus
and placenta, growth of the foetus, and expansion of the
maternal blood volume.
Continued FA supplementation with 0.4 mg/day in tri-
mesters 2 and 3 of pregnancy can increase maternal and
cord blood folate status and prevent the increase in homo-
cysteine concentration that otherwise occurs in late preg-
nancy [128].
However, the effect of folate supplementation through-
out pregnancy on several other health outcomes is
unclear. Observational studies suggest a potential benefit
of good maternal folate status on birth weight, placental
weight or length of gestation [129,130]. In contrast, sup-
plementation trials have shown equivocal results.
The meta-analysis of Fekete et al. [131] demonstrated
significant dose–response relationship between folate in-
take and birth weight. However, the results indicated no
evidence of any effect of supplementation on placental
weight or length of gestation.
In 2013 the Cochrane meta-analysis [132] conducted to
assess the effectiveness of FA supplementation during
pregnancy on maternal health and pregnancy outcomes
provided non-conclusive evidence of the benefits of
supplementation on pregnancy outcomes: there was no
impact on preterm birth (RR = 1.01, 95% CI 0.73-1.38) or
stillbirths/neonatal deaths (RR = 1.33, 95% CI 0.96-1.85).
However, improvements were seen in the mean birth
weight (mean difference (MD) = 135.75, 95% CI 47.85-
223.68). The included studies did not report on the impact
of FA supplementation on miscarriage or pre-eclampsia.
Pre-eclampsia is a leading cause of indicated preterm
delivery and accounts for 25% of very low birth weight
infants. Furthermore, pre-eclampsia may also increase
the risk of cardiovascular disease in the offspring through
“foetal origin of adult diseases” [133] and women with a
history of pre-eclampsia continue to be at increased risk
for future cardiovascular events [14,15]. As the review of
Wen et al. [134] suggests, while earlier studies showed
protective effect of FA on reduced risk of pre-eclampsia
[81-84], some recent studies failed to find such an effect
[87,88]. Selection bias, confounding factors and the
low dose of FA used could account for these differ-
ences. Given the disease burden of pre-eclampsia, novel
preventions such as FA need to undergo proper scientific
investigation [134].
The relative paucity of data indicates that there is
an urgent need to develop further studies focusing on
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first trimester. More well-designed, large-scale RCTs
are needed to establish the benefits of FA during preg-
nancy before supplementation throughout pregnancy can
be recommended on these grounds.
The Dutch and Italian trials might provide useful
information to clarify this possible association.
Safety issue
The safety of FA supplementation has been the subject
of some debate. When focusing on side effects in the
women of childbearing age, the target population of pre-
conceptional supplementation programmes, the only side
effect to be considered is an increase of dizygotic twins, as
suggested by a Swedish study [135] which, however, did
not sufficiently allow for in vitro fertilization (IVF) and
sub-fertility treatments [136]. Moreover, a Norwegian
study, analogous to the Swedish one, showed that the as-
sociation between peri-conceptional FA supplementation
and dizygotic twins disappeared after exclusion of known
IVF pregnancies, and accounting for underreporting of
both IVF pregnancies and folate use [137]. The meta-
analysis of Muggli et al. [138] suggests that the hypothesis
of the increase in dizygotic twins is still to be demon-
strated (OR = 1.26, 95% CI 0.91-1.73 for pre-conceptional
supplementation and dizygotic twins; OR = 1.02, 95% CI
0.85-1.24 for overall twins), that it would need more data
to be seriously considered and, if true, it would only cause
a very limited increase.
Moreover, questions have emerged about the role of in
utero exposure to folate through maternal intake and
the development of asthma and atopic disease [139].
Causes of asthma are considered to be an interaction of
both genetic and environmental risk factors, and the im-
pact of nutrition and other exposures during pregnancy
on long-term health and development of children has
been of increasing interest. The meta-analysis from the
National Center on Birth Defects and Developmental
Disabilities in Atlanta, United States [140] provided no
evidence of an association between maternal FA supple-
ment use (compared with no use) in the pre-pregnancy
period through the first trimester and asthma in child-
hood (summary risk estimate = 1.01, 95% CI 0.78-1.30),
although this finding was limited by the small number of
studies.
In general, population concerns about FA were mostly
related to the effect of masking pernicious anaemia due
to B12 deficiency and to the possible effects on cancer.
Current exposure to FA through fortification in the
United States has been reported not to increase the risk
of masking anaemia [141]. Regarding the cancer, to see
whether the randomized trials of FA show an increase or
decrease in cancer risk over a period of just a few years,
Vollset et al. [142] conducted collaborative meta-analysesof site-specific cancer incidence during the scheduled
treatment period among 50,000 individuals from all avail-
able large cardiovascular and adenoma trials. They found
that FA supplementation does not substantially increase
or decrease incidence of site-specific cancer during the
first 5 years of treatment (RR = 1.06, 95% CI 0.99-1.13).
Objectives
This project is a joint effort by research groups in Italy
and the Netherlands. In both countries, the additional
effect of peri-conceptional FA supplementation of 4 mg/
day compared to the 0.4 mg/day standard dose will be
assessed. In the Netherlands, the effect of continued FA
supplementation in the second and third trimesters of
pregnancy will be studied.
Italian RCT
The primary objectives are:
 to promote the implementation of pre-conceptional
counselling in a formal and structured way and with
defined procedures, to support a wider prevention of
CMs and maternal-infant health;
 to assess the effect of peri-conceptional FA
supplementation of 4 mg/day compared to the
0.4 mg/day standard dose on reducing the occurrence
of CMs.
Other aims of this study include comparing severity of
CMs in offspring of trial mothers, rates of selected CMs,
rates of miscarriage, pre-eclampsia, preterm birth, small
for gestational age, abruptio placentae.
Dutch RCT
The primary objectives are:
 to assess the effect of peri-conceptional FA
supplementation of 4 mg/day compared to the
0.4 mg/day standard dose on the prevalence of CMs;
 to assess the effect of 0.8 mg vs 0.2 mg FA
supplementation in the second and third trimesters
of pregnancy on the prevalence of preterm birth and
pre-eclampsia.
The project is currently going on. Despite a specific
recruitment strategy in both countries, the lack of
acknowledged clinical activity defined as preconceptional
counselling, together with the absence of a routine setting
which women planning pregnancy naturally refer to, the
study cannot maintain the planned trend of recruitment.
Nonetheless, considering the relative paucity of data
and the increasing interest toward the effect of FA also
on other end points of the pregnancy, the need to
develop further studies focusing on health outcomes of
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jects recruitment, the research group is still engaged in
the assessment of the effect of peri-conceptional FA sup-
plementation of 4 mg/day compared to the 0.4 mg/day
standard dose in reducing the occurrence of the main
adverse pregnancy outcomes. The following were grouped
together: CMs, miscarriage, pre-eclampsia, preterm birth,
small for gestational age, abruptio placentae.
Methods/Design
Study design
Italian RCT
The present study is a randomized, double-blind, con-
trolled trial evaluating whether supplementation with
4 mg/day of FA reduces the overall risk of major adverse
pregnancy outcomes in the population in comparison to
the standard recommended dose of 0.4 mg/day.
Dutch RCT
The study is an RCT, with four intervention arms. Ini-
tially, two groups are formed: 4.0 mg FA vs 0.4 mg FA
supplementation peri-conceptionally and both of those
groups will be split at 12 weeks of gestation into a group
with 0.2 mg FA until the end of pregnancy and a group
with 0.8 mg FA until the end of pregnancy:
1) 0.4 mg of FA from 4 weeks pre-conception to
12 weeks of gestation, and 0.2 mg FA
supplementation after 12 weeks of gestation;
2) 0.4 mg of FA from 4 weeks pre-conception to
12 weeks of gestation, and 0.8 mg FA
supplementation after 12 weeks of gestation;
3) 4.0 mg of FA from 4 weeks pre-conception to
12 weeks of gestation, and 0.2 mg FA
supplementation after 12 weeks of gestation;
4) 4.0 mg of FA from 4 weeks pre-conception to
12 weeks of gestation, and 0.8 mg FA
supplementation after 12 weeks of gestation.
Study population
Italian RCT
Women of childbearing age, 18–44 years, who intend to
become pregnant within 12 months are eligible for the
study. All eligible women who show up at obstetric and
gynaecological clinics, assisted reproduction centres, fam-
ily planning services, general practitioners and paediatri-
cians are invited to visit the randomization centres for a
complete pre-conception counselling and a talk about
participating in the study.
Women are excluded if they: (a) are pregnant, (b) do not
intend to become pregnant, (c) are younger than 18 and
older than 44 years, (d) are planning to move to an area
where the study is not implemented, (e) do not understand
Italian, (f) do not have a phone, (g) are affected by epilepsy,even not treated with anti-convulsant drugs, (h) are
affected by diabetes, (i) have suffered from cancer or a
serious disease (e.g.: Crohn disease, rheumatoid arthritis,
ulcerative colitis), (j) are being treated with antifolates or
have recently been treated with it, like methotrexate, (k)
abuse or have abused alcohol, (l) are obese (BMI ≥30), (m)
are vegetarian, (n) had a previous pregnancy with NTD or
any other congenital structural birth defects, (o) are affec-
ted or have a partner that is affected by NTD, have a
relative (in her family or in the partner’s family) affected by
NTD, (p) have a family medical history of breast cancer or
colorectal cancer, (q) have a personal or family history of
an hereditary syndrome like familiar adenomatous polyp-
osis or hereditary nonpolyposis colorectal cancer, (r) report
allergy to FA, (s) present contraindications to FA use, (t)
are affected by megaloblastic anaemia, (u) take defined
dosages of FA for directions other than those listed in the
above exclusion criteria.
Dutch RCT
All women living in the Northern region of the Netherlands
aged between 18 and 45 years who want to become
pregnant within 12 months are eligible for participation
in the study.
Women are excluded if they: (a) had previous offspring
with NTD, (b) do not give informed consent, (c) do not
understand Dutch, (d) plan to move to an area where
the study is not implemented, (e) use FA antagonists, (f )
are affected by diabetes, megaloblastic anaemia and/or
cancer (previous cancer or abnormal PAP smears), (g)
are already pregnant at the time of inclusion or within
4 weeks after the start of the intervention, (h) take high
doses of FA for any other reason.
Recruitment
Italian RCT
In Italy, as well as in other countries, there is no recog-
nized clinical activity defined as “pre-conceptional coun-
selling”. All women planning their pregnancy who discuss
their intention to hospital and community gynaecologists,
general practitioners, paediatricians, and obstetricians
in the various areas of Italy are invited to refer to the
randomization centres to receive fully structured pre-
conceptional counselling according to the standard rec-
ommendations and, if consenting, to be recruited into the
study and randomized.
The invitation is particularly focused on making the
woman and the couple aware of the importance of com-
plete pre-conceptional counselling, as a means of reducing
possible adverse events in the human reproduction
process. FA supplementation is one of the actions pro-
moted by the pre-conceptional counselling. The recruiting
investigators explain such preventive intervention and its
objectives to the women and highlight the possibility to
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contact the randomization centres is reinforced by an ad
hoc informative sheet.
The randomization centres are obstetric and gynaeco-
logical clinics, assisted reproduction centres, family plan-
ning services, and general practitioners.
Dutch RCT
In the Netherlands, eligible women are primarily ap-
proached through proactive recruitment campaigns
conducted by community pharmacies (CPs). Inclusion
takes place in a coordinated campaign run by the com-
munity pharmacists and the general practitioner of the
participant.
Since individual pre-conception care is currently not
available on a large scale in the Netherlands, no “natural”
existing starting point for the recruitment procedure is
available. The target population from which the actual
recruitment has to take place consists of all women of
childbearing age that have the intention to become preg-
nant within the next 12 months. The actual inclusion
(final step of the recruitment process) mainly takes place
during CP visits, in which consent is given.
Personal informative mailings from CPs are sent to all
female clients in the age group 25–35, accompanied by a
letter that requests, if appropriate, considering participa-
tion in the trial on behalf of the pharmacist. In addition,
permanent public information are present in the CP and
recurrent personal information are given at delivery of
certain Over-The-Counter and prescribed drugs in the
CP. Other health professionals contribute towards inform-
ing the target group: posters and leaflets are available at
well baby clinics and with primary care physicians. At
some sport schools and child care centres posters are
present. Representatives of the research team promoted
participation in the trial and gave information at fairs
targeted at women of reproductive age.
Randomization procedures
Italian RCT
After giving informed consent, women are randomly
assigned to receive a pill containing 4 mg of FA (treatment
in study) or 0.4 mg of FA (referent treatment) daily. The
randomization code is generated by a web-based patient
randomization system, stratified according to the enrol-
ment site and the maternal age group. The study is
double-blinded: subjects, investigators and research staff
are blinded to the randomization assignments.
Dutch RCT
After giving informed consent, women are randomized
to one of the four groups. Randomization is not stratified.
Every four participants per research centre are assigned to
a different study group, resulting in equal distributionsamong the study groups. The study is double-blinded:
subjects, investigators and research staff are blinded to the
randomization assignments.
Interventions
Italian RCT
At the enrolment visit, full pre-conceptional counselling is
offered to women according to standard guidelines. All
the eligible women are interviewed by the investigators
using a structured form to evaluate socio-demographic
and lifestyle characteristics, past and present health status,
previous pregnancy outcomes, and the previous four
months of food intake.
Subjects who show interest in participating in the
study and who meet the inclusion criteria, in the absence
of exclusion criteria and after giving informed consent, are
randomized to either 4 mg or 0.4 mg of FA.
All women are given a box containing 130 pills,
according to the blinded randomization arm. All women
are then recommended to take one pill per day and to
contact the enrolment centre when only 20 pills are left
in the box so that they get another box of 130 pills. After
randomization, enrolled women are interviewed every
4 months by the investigators (when they contact the
randomization centre to get another box of FA pills), to
evaluate the pregnancy status.
If women become pregnant, they will take the FA until
the end of the 12th completed gestational week. If they
have not become pregnant after 12 months of FA supple-
mentation, the women will be removed from the study.
Dutch RCT
Women in all intervention groups receive identical pills,
containing two different doses of FA (4 or 0.4 mg).
Women start taking the pills after randomization, but at
least 4 weeks before conception, and will receive new pills
from their pharmacy every 4 months.
At 12 weeks of gestation, all women will receive a new
set of pills, half of them receiving 0.2 mg supplements
and half 0.8 mg of FA. Again the pills are identical. New
pills are issued once more during pregnancy (25 weeks
of gestation).
Information collected and follow-up
Italian RCT
At the enrolment visit, all the eligible women are inter-
viewed by the investigators using a structured form to
evaluate socio-demographic and lifestyle characteristics,
past and present health status, previous pregnancy out-
comes, and the previous four months of food intake.
After randomization, enrolled women are interviewed
by the investigators every 4 months (if not pregnant),
when they contact the randomization centre to get an-
other box of FA pills. The interview at 4-8-12 months is
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nancy status, current health conditions, and experimen-
tal medicine intake.
Enrolled randomized women who are diagnosed as
being pregnant during the study period and who take
the FA until the end of the 12th completed gestational
week, are invited to come back to the randomization
centre to return the remaining pills and to update their
status.
They will be interviewed at the expected 16, 24 and
40 weeks of gestation by a trained Health Care Provider
(HCP) by phone using a structured form to evaluate the
pregnancy outcome. All the pregnancy outcomes, irre-
spective of the information reported by the woman at
the interview, will be checked in the hospital’s clinical
records by a trained HCP.
The health status of live births will be evaluated by a
trained HCP through an interview with the attending
physician using a structured questionnaire when the
child reaches the age of 1 month, 3 months and 1 year,
and an interview with the parents when the child is
1 year old.Dutch RCT
Most data are gathered through questionnaires in the
Netherlands. Information on all CMs of live births, still-
births and terminations of pregnancy following prenatal
diagnosis are derived from the database of EUROCAT,
where virtually all CMs are registered. Data about the
diagnosis and the medical history are collected in a
standardized procedure of high quality.
Variables derived from medical records are: birth weight,
gestational age, diseases during pregnancy (diabetes, high
blood pressure), abruptio placentae, Apgar score.
In a short questionnaire, women answer questions on
compliance to trial medication, the use of vitamin sup-
plements and the use of alcohol, tobacco and drugs.
These questions will be repeated each time they pick up
their supplements at the pharmacy.
Follow-up: after randomization, women receive a new
set of pills every 4 months at the pharmacy, until a
period of 12 months has elapsed without them getting
pregnant or until the end of their pregnancy (live birth,
stillbirth, spontaneous abortion or termination). After the
pregnancy has been completed, women and their general
practitioners will receive a final questionnaire about preg-
nancy outcomes by mail.Definition of treatment compliance and withdrawal
Italian RCT
Compliance to FA supplementation is evaluated by
counting the pills not taken and that remain in the given
box at the randomization centre.Three categories will be defined for compliance status:
(a) fully treated women: those women who will take at
least 70% of the expected pills during the full peri-
conceptional period (1 month before and 3 months after
last menstruation); (b) partially treated women: women
who will take between 30% and 69% of the pills during
the full peri-conceptional period, (c) non-treated women:
less than 30% of the pills. The last category will be
considered as non-compliant.
Patients may be withdrawn and excluded from the
“protocol analysis” but evaluated at the “intention-to-
treat” analysis for any of the following reasons: any
protocol violation, non-compliance, lost to follow-up,
patient withdrawn at her own request, for reasons other
than those above.
Dutch RCT
Women are asked to return all pills they have not used to
the pharmacy every time they collect a new set of pills, in
order to check compliance with FA supplementation.
All analyses will be performed according to the
intention-to-treat principle. In addition, alternative per
protocol analyses will be performed, excluding all partici-
pants who were not compliant with FA supplementation.
For the analysis on the effect of FA supplementation on
CMs, groups 1 and 2 (low dose) and 3 and 4 (high dose)
will be combined, since no interaction between early FA
and late FA supplementation is expected.
Outcome measures
Italian RCT
The primary study outcome is the total number of adverse
pregnancy outcomes as listed above.
Dutch RCT
The primary outcomes include all FA-related CMs.
Preterm birth is defined as a gestational age <37 weeks.
Pre-eclampsia is defined as a systolic blood pressure ≥
140 mmHg and/or diastolic blood pressure ≥ 90 mmHg
after 20 weeks of gestation among women with previ-
ously normal blood pressure, combined with proteinuria
(≥300 mg/24 hours).
Sample size
In the original protocols, sample size was computed
considering CMs as end point. However, given the
increasing interest toward the effect of FA supplementa-
tion on all pregnancy outcomes on the one hand, and
the difficulties encountered in subjects recruitment on
the other hand, we foresee to analyze the data considering
all the adverse outcomes of pregnancy taken together
in a global end point (e.g.: CMs, miscarriage, pre-
eclampsia, preterm birth, small for gestational age, abrup-
tio placentae).
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pregnancy outcomes has an estimated frequency of 30%
(unpublished observation), a total of about 1,000 preg-
nancies need to be evaluated to detect an absolute
reduction of the frequency of 8% with allocation ratio
1:1, alpha error of 0.05, power of 80%.
After one year of pregnancy planning or active preg-
nancy search, a pregnancy rate of 80-85% is expected.
Since the sample size needed to analyze outcomes separ-
ately is large, this project also promotes an international
prospective meta-analysis.
Data analysis
The analysis will be conducted by protocol and by
intention to treat. A multivariate model will be used
where unbalanced characteristics will be considered. A
subgroup analysis will be performed for women with
assisted reproduction.
Ethical considerations
Italian RCT
The project has been approved by the ethical committee
of the randomization centres, and all subjects provide
written informed consent.
Dutch RCT
The project has been approved by the ethical committee
of the VU University Medical Center, and all subjects
provide written informed consent.
Data Safety Monitoring Committee
Italian and Dutch RCT
The study will be interrupted if:
 there is evidence that the study drug causes
suspected unexpected serious adverse reactions
(SUSAR) or serious adverse events (SAE) in the
short or long term;
 the frequency of any reproductive adverse event or
pregnancy complication in the overall group of
women in the study is higher than the expected
frequency.
To regularly check this, the Data Safety Monitoring
Board (DSMB) will evaluate the global frequency of
reproductive adverse events or pregnancy complications
in the total sample of randomized women, and will com-
municate it to the General Coordination Centre (GCC).
Relevance for society
Between 200,000 and 300,000 cases of NTDs are born
each year worldwide. Other CMs that might be pre-
vented with FA supplementation are heart anomalies,
limb defects, urinary tract malformations, oral clefts andDown syndrome. These anomalies far outnumber the
figures for NTDs. It must be stressed that the potential
impact on child health is huge. Even a 13% reduction of
all CMs means 39,000 healthy infants per year out of 10
million births in the WHO European Region. The most
common and severe CMs are included among a selected
group that may be more sensitive to the preventive action
of FA (NTDs, oral clefts, cardiac defects, urinary tract
anomalies, limb reduction defects, omphalocele, anal atre-
sia). Even an apparently small decrease (e.g.: 20-30%) of the
frequency of all CMs through a primary prevention inter-
vention is an extremely important public health issue, since
we can secure the health of a great number of children that
would otherwise be affected as well as save money.
All these CMs have a huge impact on the health,
quality of life, and life expectancy of the children. They
also have a major impact on the lives and quality of life
of their family. If the preventive effect of FA for CMs
other than NTDs were to be proven, this fact could be
used to further conduce the pre-conceptional use of FA
supplements through patient education strategies, thereby
increasing the overall effect of FA prevention. If higher
doses of FA supplementation appear to be more effective
than the now recommended daily dose of 0.4 mg, this
would be an improvement of an existing intervention with
huge impact.
But it is not only CMs that might be affected by FA
supplementation. The risk of pre-eclampsia and preterm
birth is also likely to be reduced by FA supplementation.
The prevention of both CMs and preterm birth will result
in a reduced perinatal death rate.
The proof of additional preventive effects of FA over
the currently accepted effects of 0.4 mg on NTDs only
has a significant impact on the need for, and the possi-
bilities to reduce, social inequalities in health.
Discussion
In conclusion, the total group of adverse pregnancy
outcomes is the single major cause of infant morbidity,
mortality and disability in all countries. Therefore even an
apparently small decrease (e.g.: 20-30%) of the frequency
of major adverse pregnancy outcomes through a primary
prevention intervention is an extremely important public
health issue, since we can secure the health of a great
number of children who would otherwise affected. Pre-
vention in this field is therefore highly important.
We designed an RCT to assess the effect of FA peri-
conceptional supplementation of 4 mg/day compared to
the 0.4 mg/day standard dose on reducing the occurrence
of major adverse pregnancy outcomes. The project will
also give the opportunity to promote fully standardized
pre-conceptional counselling in all the women contacted
to participate and then to promote a wider prevention of
adverse pregnancy outcomes and maternal-infant health.
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